Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.

The oncologist - 11 Dec 2023

Pruis Melinda A, Krebs Matthew G, Plummer Ruth, De Vos Filip, Angevin Eric, Prenen Hans, Forster Martin D, Clack Glen, Van der Aa Annegret, Tjwa Marc, Jansen Ellen, Perera Timothy, Lolkema Martijn P

Abstract excerpt

INTRODUCTION: Targeted therapy in non-small cell lung cancer (NSCLC) patients with mesenchymal epithelial transition (MET) exon 14 skipping mutations (METex14) and MET amplifications has improved patients' outcomes. The development of more potent MET kinase inhibitors could further benefit these patients. The aim of this trial is to determine the safety and recommended phase 2 dose (RP2D) of OMO-1 (an oral dual...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Neoplasms, Second Primary

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 37260332
DOI: 10.1093/oncolo/oyad146
PMCID: PMC10712729

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.PMID 37260332Read ↗

Efficacy and safety of tepotinib in MET‑altered non‑small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

A phase II study of tepotinib in patients with advanced solid cancers harboring MET exon 14 skipping mutations or amplification (KCSG AL19-17).Semantic proximity Read ↗

Current Trial Report: A Multicenter Phase I/Ib study of Capmatinib Plus Trametinib in Patients With Metastatic Nonsmall Cell Lung Center Harboring MET Exon 14 Skipping Mutations and Other MET-Alterations.Semantic proximity Read ↗

MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutationsSemantic proximity Read ↗

Safety of MET Tyrosine Kinase Inhibitors in Patients With MET Exon 14 Skipping Non-small Cell Lung Cancer: A Clinical Review.Semantic proximity Read ↗

Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.Semantic proximity Read ↗

Targeting MET in Non-Small Cell Lung Cancer (NSCLC): A New Old Story?Semantic proximity Read ↗

MET-Targeted Therapies and Clinical Outcomes: A Systematic Literature Review.Semantic proximity Read ↗

New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.Semantic proximity Read ↗

Tepotinib in patients with MET exon 14 skipping non-small cell lung cancerSemantic proximity Read ↗

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.